LIDODERM (nda020612)- (5%)

Generic Name	LIDOCAINE	Innovator	TEIKOKU PHARMA USA
Dosage	5%
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2016-Dec-23	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	LIDODERM is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
5	0	5

Other Developers

Total Other Developers	5

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
5%	**	**	Up	4	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	4

Manufacturing Details of LIDODERM